Search

The article reports that Mylan Pharmaceutical Inc.'s abbreviated new drug application (ANDA) has been accepted for filing by the Food and Drug Administration in the U.S. The product called glatiramer acetate injection is a generic version of Teva's Copaxone, a product indicated for the treatment of multiple sclerosis. Moreover, Mylan has collaborated with Natco Pharma Ltd. and is granted the rights to exclusively distribute glatiramer acetate pre-filled syringes in the U.S. and other countries.